Actively Recruiting
Open-label Study of GT719 Injection for Adults with Recurrent or Refractory CD19 Positive B-cell Blood Cancers
Led by Grit Biotechnology · Updated on 2026-09-18
46
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GT719 Injection in a phase III clinical trial for adults with relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma B-NHL and B-acute lymphoblastic leukemia B-ALL. The study aims to assess the safety, how the treatment behaves in the body, and its effects on these blood cancers in a total of about 46 participants. Participants will receive GT719 Injection as the treatment. The study includes a dose escalation phase to find the appropriate dose, followed by an expansion phase to further evaluate the treatment. This is a single-arm, open-label trial where all participants receive the investigational drug. During the study, participants will be monitored for adverse events from the time of infusion through 12 months of treatment. Researchers will also measure treatment responses at 28 days after the first infusion and at 2, 3, 6, 9, and 12 months. Safety and effectiveness assessments, including physical fitness status and CD19 positivity, will be conducted throughout the study period.
CONDITIONS
Brief Title
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Research Team
D
Dehui Zou
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here